Moderna Inc
MRNA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$437.00 | Yklv | Pcwrmqdw |
Moderna's mRNA Technology Is Showing Promise Beyond COVID-19
Business Strategy and Outlook
Moderna's mRNA technology has gained rapid validation as sales of its COVID-19 vaccine soared in 2021, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape for innovative vaccines.